Evidence map›Paper›PMID 27184605›Full record

Trial reportThe American journal of drug and alcohol abuse2016

Coadministration of disulfiram and lorazepam in the treatment of alcohol dependence and co-occurring anxiety disorder: an open-label pilot study.

Michael P Bogenschutz, Snehal Bhatt, Juliane Bohan, Bellelizabeth Foster, Paul Romo, Claire E Wilcox, J Scott Tonigan

Open access · greenAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The American journal of drug and alcohol abuse, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Michael P Bogenschutza Department of Psychiatry , New York University School of Medicine , New York , NY , USA.
Snehal Bhattb Department of Psychiatry and Behavioral Sciences , University of New Mexico Health Sciences Center , Albuquerque , NM , USA.
Juliane Bohanb Department of Psychiatry and Behavioral Sciences , University of New Mexico Health Sciences Center , Albuquerque , NM , USA.
Bellelizabeth Fosterb Department of Psychiatry and Behavioral Sciences , University of New Mexico Health Sciences Center , Albuquerque , NM , USA.
Paul Romob Department of Psychiatry and Behavioral Sciences , University of New Mexico Health Sciences Center , Albuquerque , NM , USA.
Claire E Wilcoxb Department of Psychiatry and Behavioral Sciences , University of New Mexico Health Sciences Center , Albuquerque , NM , USA.
J Scott Toniganc Center on Alcoholism, Substance Abuse, and Addictions , University of New Mexico , Albuquerque , NM , USA.
University of New Mexico · USNew York University · US

Funding

A Program of Research and Mentorship on Alcoholism and Co-occuring DisordersK24AA016555 · NIAAA · UNIVERSITY OF NEW MEXICO · PI BOGENSCHUTZ, MICHAEL PARKS · 2007 to 2011
$854k
Research and Mentoring in AA-related Mechanisms of ChangeK24AA021157 · NIAAA · UNIVERSITY OF NEW MEXICO · PI TONIGAN, J. SCOTT · 2013 to 2017
$850k
NIAAA NIH HHS K24 AA016555NIAAA NIH HHS K24 AA021157
6 · The paper itself

Abstract

backgroundAnxiety is common among persons with alcohol use disorder during early abstinence from alcohol. Although benzodiazepines are effective for short-term treatment of anxiety, they are rarely used beyond acute detoxification due to concerns about misuse or interactions with alcohol.

objectivesWe conducted an open-label trial to explore the effects of coadministering lorazepam and disulfiram to alcohol-dependent patients with anxiety disorder symptoms. The rationale for this model is to minimize the risks of the benzodiazepine, while also potentially enhancing adherence to disulfiram.

methodsForty-one participants with DSM-IV alcohol dependence who also met syndromal criteria for anxiety disorder with or without co-occurring major depressive syndrome initiated treatment with lorazepam (starting dose 0.5 mg three times daily) and disulfiram (starting dose 500 mg three times weekly). Participants received 16 weeks of monitored pharmacotherapy with manualized medical management.

resultsAdherence to treatment decreased steadily with time (85.4% at 4 weeks, 36.6% at 16 weeks). Participants showed significant increases in percent abstinent days during treatment and at 24 weeks follow-up. Large reductions in anxiety, depression, and craving were observed during treatment, and improvement remained significant at 24 weeks. Duration of adherence with disulfiram strongly predicted abstinence at 16 weeks. There was no evidence of misuse of lorazepam or dose escalation during the study.

conclusionLorazepam can be safely used for short-term treatment of anxiety in combination with disulfiram treatment of alcohol use disorder. However, it is not clear that making lorazepam dispensing contingent on adherence to disulfiram enhances retention in disulfiram treatment.

Indexed as

AdultAlcoholismAnxiety DisordersCravingDisulfiramDrug MonitoringDrug Therapy, CombinationFemaleHumansLorazepamMajor Depressive DisorderMalePilot ProjectsTreatment OutcomeYoung AdultDisulfiramLorazepamAlcohol dependencealcohol use disorderanxietybenzodiazepinedisulfiramlorazepam

Identifiers

PMID27184605
PMCPMC5903270
OpenAlexW2400212909

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.